Charles River’s experience with oncology drug discovery and development spans all phases, from target identification to IND. Utilizing the most effective combination of tools available to identify promising compounds, our broad range of models and support services allows clients to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates. Our team can support your development of novel cancer therapeutics, every step of the way.
Charles River maintains a comprehensive portfolio of mouse and rat models with varying levels of immunodeficiency and phenotypic characteristics to support your oncology research and development programs. Whether you are in basic research or discovery, Charles River is positioned to help you accelerate your cancer research.
Basic Research Products & Services
Cancer drug discovery has advanced significantly in the last decade. Small molecules and biologics are both widely used, along with combination therapies, as science moves towards a personalized approach to treatment. The success of cancer immunotherapies has been a particularly exciting development, and immuno-oncology has justifiably become an area of intense interest.
As researchers explore the possibilities in oncology and immuno-oncology, the tool kits of drug discovery scientists are becoming increasingly more sophisticated and translational. Utilizing the most effective combination of in vitro and in vivo study models and advanced biomarker analysis tools available to identify and characterize promising compounds, combined with our broad range of biology, chemistry, and pharmacology expertise, allows our scientists to establish the most appropriate study design and screening method for any target and modality.
Services and Tools for Oncology Drug Discovery
- Posters from the AACR Annual Meeting 2018
- Tumor Model Compendium
- Webinar Replay: Designing a Novel Cancer Drug - From Hit ID to Candidate
- Oncology drug discovery overview sheet
- Delivering Innovation through Collaboration in Cancer Drug Discovery
- CORE Library
- Ion channel selectivity profiling: oncology datasheet
From the initial stages through clinical trials, Charles River provides safety assessment solutions to your oncology programs and projects. Customized analytical and bioanalytical assays, toxicology studies, and pathology endpoints along with expertise working with oncology products across the portfolio means we are an ideal partner with whom to bring your new cancer therapies and drugs to market.
Safety Assessment Services
We offer full-service support across the entire drug discovery and development continuum, including many products and services not specific to therapeutic area or indication.
Serving the needs of both small and large molecule developers, we offer a broad range of standard and specialized laboratory services to complement and enhance drug development programs, from discovery through safety and clinical trials. From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services that comply with worldwide regulatory restrictions for the preclinical development of pharmaceuticals.
We provide a comprehensive range of testing programs and equipment to support pharmaceutical development. Our biologics testing solutions and portfolio of microbial quality control systems and services help clients ensure the safety, quality and compliance of their products. We support large molecule manufacturing from early preclinical formulation development through clinical and commercial manufacturing and release.
Exceptional support of the entire drug discovery and development process is a Charles River hallmark. As a customer-focused organization committed to advancing science and helping clients reach their goals, we continually strive to develop solutions that extend our support of their efforts. Because our industry-seasoned professionals have followed the same journey as our clients, we can provide insight into the bigger picture, advice on best practices, skilled staff to extend resources and targeted training to meet the unique challenges they face along the way.